Back to top
more

AdaptHealth (AHCO)

(Real Time Quote from BATS)

$8.96 USD

8.96
581,459

-0.26 (-2.82%)

Updated Sep 17, 2025 03:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (87 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

WAT Earnings & Sales Surpass Estimates in Q4, Shares Rise

by Zacks Equity Research

WAT's fourth-quarter 2024 results reflect strong pharma growth and robust gains across all regions. However, forex headwinds hurt.

Zacks Equity Research

AHCO or ABT: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

AHCO vs. ABT: Which Stock Is the Better Value Option?

Zacks Equity Research

Should Value Investors Buy AdaptHealth (AHCO) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

AHCO vs. HLN: Which Stock Is the Better Value Option?

by Zacks Equity Research

AHCO vs. HLN: Which Stock Is the Better Value Option?

Zacks Equity Research

Should Value Investors Buy AdaptHealth (AHCO) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Implied Volatility Surging for AdaptHealth (AHCO) Stock Options

by Zacks Equity Research

Investors need to pay close attention to AdaptHealth (AHCO) stock based on the movements in the options market lately.

Zacks Equity Research

AdaptHealth Corp. (AHCO) Surpasses Q3 Earnings Estimates

by Zacks Equity Research

AdaptHealth (AHCO) delivered earnings and revenue surprises of 5% and 0.35%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zimmer Biomet (ZBH) Misses Q3 Earnings Estimates

by Zacks Equity Research

Zimmer (ZBH) delivered earnings and revenue surprises of -0.57% and 1.12%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AHCO or LZAGY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

AHCO vs. LZAGY: Which Stock Is the Better Value Option?

Zacks Equity Research

Are Investors Undervaluing AdaptHealth (AHCO) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?

by Zacks Equity Research

Here is how AdaptHealth Corp. (AHCO) and BellRing Brands (BRBR) have performed compared to their sector so far this year.

Zacks Equity Research

Do Options Traders Know Something About AdaptHealth (AHCO) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to AdaptHealth (AHCO) stock based on the movements in the options market lately.

Zacks Equity Research

Abbott Stock Gains on Q3 Earnings Beat, Margins Expand

by Zacks Equity Research

ABT delivers a strong underlying base business performance in the third quarter of 2024.

Zacks Equity Research

Neogen Q1 Earnings Miss Estimates, Margins Crash

by Zacks Equity Research

NEOG's Food Safety and Animal Safety businesses witness a year-over-year decrease in revenues in the first quarter of fiscal 2025.

Zacks Equity Research

AHCO vs. LZAGY: Which Stock Is the Better Value Option?

by Zacks Equity Research

AHCO vs. LZAGY: Which Stock Is the Better Value Option?

Zacks Equity Research

Is AdaptHealth (AHCO) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

AdaptHealth Corp. (AHCO) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

AdaptHealth (AHCO) delivered earnings and revenue surprises of 10.53% and 0.45%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Myriad Genetics (MYGN) Expands in MRD Testing With New Collab

by Zacks Equity Research

Myriad Genetics (MYGN) inks an agreement with Personalis to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease. The idea is to broaden patient access to the benefits of MRD testing.

Zacks Equity Research

Implied Volatility Surging for AdaptHealth (AHCO) Stock Options

by Zacks Equity Research

Investors need to pay close attention to AdaptHealth (AHCO) stock based on the movements in the options market lately.

Zacks Equity Research

AHCO or PBH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

AHCO vs. PBH: Which Stock Is the Better Value Option?

Zacks Equity Research

Asensus Surgical (ASXC) Inks a Merger Agreement With KARL STORZ

by Zacks Equity Research

KARL STORZ is set to acquire all of the outstanding shares of Asensus Surgical (ASXC) for $0.35 per share in cash, making Asensus a subsidiary of KARL STORZ.

Zacks Equity Research

AdaptHealth Corp. (AHCO) Lags Q1 Earnings Estimates

by Zacks Equity Research

AdaptHealth (AHCO) delivered earnings and revenue surprises of -66.67% and 2.78%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Lantheus Holdings (LNTH) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 9.03% and 5.87%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Philips (PHG) Q1 Earnings Beat Estimates, Revenues Fall Y/Y

by Zacks Equity Research

Philips' (PHG) first-quarter results benefit from strong momentum across the Diagnosis & Treatment and Personal Health businesses. However, softness in the Connected Care business is a concern.

Zacks Equity Research

AHCO vs. BSX: Which Stock Is the Better Value Option?

by Zacks Equity Research

AHCO vs. BSX: Which Stock Is the Better Value Option?